Archibald et al., 1987 - Google Patents
Secretory IgA antibodies to human immunodeficiency virus in the parotid saliva of patients with AIDS and AIDS-related complexArchibald et al., 1987
- Document ID
- 4699707643101307291
- Author
- Archibald D
- Barr C
- Torosian J
- McLane M
- Essex M
- Publication year
- Publication venue
- The Journal of infectious diseases
External Links
Snippet
1. Centers for Disease Control. Revision of the case definition of acquired immunodeficiency syndrome for national reporting-United States. MMWR 1985; 34: 373-5 2. Stahl RE, Friedman-Kien A, Dubin R, Marmor M, Zolla-Pazner S. Immunologic abnormalities in …
- 206010000565 Acquired immunodeficiency syndrome 0 title abstract description 12
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Archibald et al. | Secretory IgA antibodies to human immunodeficiency virus in the parotid saliva of patients with AIDS and AIDS-related complex | |
| Archibald et al. | Antibodies to human T-lymphotropic virus type III (HTLV-III) in saliva of acquired immunodeficiency syndrome (AIDS) patients and in persons at risk for AIDS | |
| Robinson Jr et al. | Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro | |
| Klatzmann et al. | HIV infection: facts and hypotheses | |
| Fultz et al. | Vaginal transmission of human immunodeficiency virus (HIV) to a chimpanzee | |
| Albert et al. | Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera | |
| Sawyer et al. | Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection | |
| Marlink | Lessons from the second AIDS virus, HIV-2 | |
| Verdier et al. | Prevalence of antibody to human T cell leukemia virus type 1 (HTLV-I) in populations of Ivory Coast, West Africa | |
| Mitsuyasu et al. | Heterogeneity of epidemic Kaposi's sarcoma. Implications for therapy | |
| Archibald et al. | Salivary antibodies as a means of detecting human T cell lymphotropic virus type III/lymphadenopathy-associated virus infection | |
| KELKER et al. | Lymphocytes from some long-term seronegative heterosexual partners of HIV-infected individuals proliferate in response to HIV antigens | |
| Cabradilla et al. | Serodiagnosis of antibodies to the human AIDS retrovirus with a bacterially synthesized env polypeptide | |
| Thiriart et al. | Antibodies to soluble CD4 in HIV-1-infected individuals | |
| Murphy et al. | A case-control study of risk factors for seropositivity to human T-lymphotropic virus type I (HTLV-I) in Jamaica | |
| Mizuma et al. | Serum IgD elevation is an early marker of B cell activation during infection with the human immunodeficiency viruses | |
| KOZLOWSKI et al. | Serum IgA subclasses and molecular forms in HIV infection: selective increases in monomer and apparent restriction of the antibody response to IgA1 antibodies mainly directed at env glycoproteins | |
| Miller et al. | Genital secretory immune response to chronic simian immunodeficiency virus (SIV) infection: a comparison between intravenously and genitally inoculated rhesus macaques | |
| Matsuda et al. | Enhancement of human immunodeficiency virus (HIV) replication in human monocytes by low titres of anti‐HIV antibodies in vitro | |
| EP1476467B1 (en) | Immunoglobulin igg3 as a marker for protecting against infectious viral diseases, and the uses of the same | |
| Fultz et al. | HIV infection of chimpanzees as a model for testing chemotherapeutics | |
| Gorse et al. | Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration | |
| SUN et al. | Variation of secretory antibodies in parotid saliva to human immunodeficiency virus type 1 with HIV-1 disease stage | |
| ShivRaj et al. | Antibodies to HIV-1 in sera from patients with mycobacterial infections | |
| Israel et al. | Nonclassical mucosal antibodies predominate in genital secretions of HIV‐1 infected chimpanzees |